Literature DB >> 32431377

Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

William V Williams1,2, Louise A Mitchell3, S Kathleen Carlson4, Kathleen M Raviele5.   

Abstract

Combined estrogen-progestogen contraceptives (oral contraceptives or OCs) and progestogen-only contraceptives (POCs) are synthetic steroids that bind to steroid hormone receptors, which are widespread throughout the body. They have a profound effect on cellular physiology. Combined OCs have been classified by the International Agency for Research on Cancer (IARC) as Group 1 carcinogens, but their findings have not been updated recently. In order to update the information and better understand the impact that OCs and POCs have on the risk of development of cancers, a comprehensive literature search was undertaken, focusing on more recently published papers. In agreement with the IARC, the recent literature confirms an increased risk of breast cancer and cervical cancer with the use of OCs. The recent literature also confirms the IARC conclusion that OCs decrease the risk of ovarian and endometrial cancers. However, there is little support from recent studies for the IARC conclusion that OCs decrease the risk of colorectal cancer or increase the risk of liver cancer. For liver cancer, this may be due to the recent studies having been performed in areas where hepatitis is endemic. In one large observational study, POCs also appear to increase the overall risk of developing cancer. OCs and POCs appear to increase the overall risk of cancer when carefully performed studies with the least intrinsic bias are considered.
SUMMARY: OCs have been classified as cancer-causing agents, especially leading to increases in breast cancer and cervical cancer. A review of the recent scientific literature was performed to see whether this still appears to be the case. The recent literature supports the cancer-causing role of OCs especially for breast cancer and cervical cancer. Studies also indicate that progesterone-only contraceptives (such as implants and vaginal rings) also can cause cancer. This is especially true for breast cancer and cervical cancer. © Catholic Medical Association 2018.

Entities:  

Keywords:  Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Contraception; Contraceptive; Endometrial cancer; Estrogen; Ovarian cancer; Progestogen

Year:  2019        PMID: 32431377      PMCID: PMC6322132          DOI: 10.1177/0024363918811637

Source DB:  PubMed          Journal:  Linacre Q        ISSN: 0024-3639


  158 in total

1.  Reproductive and hormonal factors and the risk of nonsmall cell lung cancer.

Authors:  Cari L Meinhold; Amy Berrington de González; Elise D Bowman; Alina V Brenner; Raymond T Jones; James V Lacey; Christopher A Loffredo; Donna Perlmutter; Sara J Schonfeld; Glenwood E Trivers; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies.

Authors:  Nan-Nan Luan; Lang Wu; Ting-Ting Gong; Yong-Lai Wang; Bei Lin; Qi-Jun Wu
Journal:  Cancer Causes Control       Date:  2014-10-31       Impact factor: 2.506

3.  Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area.

Authors:  Thérèse Truong; Laurent Orsi; Dominique Dubourdieu; Yannick Rougier; Denis Hémon; Pascal Guénel
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

4.  Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.

Authors:  G L Maxwell; J M Schildkraut; B Calingaert; J I Risinger; L Dainty; P A Marchbanks; A Berchuck; J C Barrett; G C Rodriguez
Journal:  Gynecol Oncol       Date:  2006-06-05       Impact factor: 5.482

Review 5.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.

Authors:  Paul Appleby; Valerie Beral; Amy Berrington de González; Didier Colin; Silvia Franceschi; Adrian Goodhill; Jane Green; Julian Peto; Martyn Plummer; Siân Sweetland
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

6.  Alcohol consumption and endometrial cancer risk: the multiethnic cohort.

Authors:  Veronica Wendy Setiawan; Kristine R Monroe; Marc T Goodman; Laurence N Kolonel; Malcolm C Pike; Brian E Henderson
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

7.  Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison.

Authors:  Huiyan Ma; Leslie Bernstein; Ronald K Ross; Giske Ursin
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

8.  Hormonal contraceptive use and breast cancer in Thai women.

Authors:  Arisara Poosari; Supannee Promthet; Siriporn Kamsa-ard; Krittika Suwanrungruang; Jirapat Longkul; Surapon Wiangnon
Journal:  J Epidemiol       Date:  2014-03-07       Impact factor: 3.211

9.  Contemporary Hormonal Contraception and the Risk of Breast Cancer.

Authors:  Lina S Mørch; Charlotte W Skovlund; Philip C Hannaford; Lisa Iversen; Shona Fielding; Øjvind Lidegaard
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

10.  Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition.

Authors:  K K Tsilidis; N E Allen; T J Key; L Dossus; A Lukanova; K Bakken; E Lund; A Fournier; K Overvad; L Hansen; A Tjønneland; V Fedirko; S Rinaldi; I Romieu; F Clavel-Chapelon; P Engel; R Kaaks; M Schütze; A Steffen; C Bamia; A Trichopoulou; D Zylis; G Masala; V Pala; R Galasso; R Tumino; C Sacerdote; H B Bueno-de-Mesquita; F J B van Duijnhoven; M G M Braem; N C Onland-Moret; I T Gram; L Rodríguez; N Travier; M-J Sánchez; J M Huerta; E Ardanaz; N Larrañaga; K Jirström; J Manjer; A Idahl; N Ohlson; K-T Khaw; N Wareham; T Mouw; T Norat; E Riboli
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

View more
  3 in total

1.  Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-04-21

2.  Hormonal Replacement Therapy and Risk of Thyroid Cancer in Women: A Meta-Epidemiological Analysis of Prospective Cohort Studies.

Authors:  Jong-Myon Bae
Journal:  J Menopausal Med       Date:  2021-12

3.  Hormonally Active Contraceptives Part I: Risks Acknowledged and Unacknowledged.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Mike Gaskins; Elvis I Seman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.